English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu“I’m honored to receive this important grant to advance our artificial intelligence research at the UC Davis Comprehensive Cancer Center so that we can better predict breast cancer risk,” said Morris, who is also a Komen Scholar. “We will develop a database of patient molecular and genomic data as well as imaging and clinical outcomes that will ultimately create personalized breast cancer risk prediction models.”
The grant is included in $14 million that Komen recently awarded. The funds support the organization’s mission to end breast cancer through funding two key focus areas: research to better detect and treat stage IV (metastatic) breast cancer and research to eliminate disparities in breast cancer outcomes.
“We are extremely proud to be able to continue our legacy of leading investments in breast cancer research, especially in light of the challenges all nonprofits faced raising funds during this pandemic year,” said Paula Schneider, president and CEO of Susan G. Komen and a breast cancer survivor. “This investment reinforces our commitment to funding innovative science from some of the leading minds in breast cancer research while also developing the next generation of scientists at a time when we have never needed them more.”
Komen has now invested about $1.1 billion in research in the nearly 40 years since its founding, the largest collective investment of any breast cancer nonprofit, and second only to the U.S. government. Visit komen.org for a full list of this year’s research grants.
